Siemens plans to list Siemens Healthineers
Siemens AG is preparing to list its separately managed healthcare unit on the Prime Standard segment of the Frankfurt Stock Exchange's Regulated Market. This move, which the company's Supervisory Board approved at its meeting today, is planned for the first half of 2018. "For Siemens Healthineers, the public listing is the next logical step and the foundation for expanding our strong position as a leading global supplier of healthcare technology," said Michael Sen, Chairman of the Siemens Healthineers Supervisory Board and the member of Siemens' Managing Board responsible, among other things, for healthcare technology.
"Frankfurt is one of the world's largest trading centers for securities, and its importance will continue to increase due to Brexit. As a highly liquid trading venue, Frankfurt is attractive for investors from around the world. The public listing will give Siemens Healthineers entrepreneurial flexibility and access to the capital market. The goal is to grow sustainably and profitably while actively shaping the paradigm shift in the healthcare industry," said Michael Sen.
For the public listing, Siemens Healthineers AG will be established. "Our preparations for the public listing are completely on schedule. The Strategy 2025 concept and the management team are in place. The legal prerequisites have largely been fulfilled. Deutsche Bank, Goldman Sachs International and J.P. Morgan have been engaged as global coordinators, and BNP PARIBAS, BofA Merrill Lynch, Citigroup and UBS Investment Bank as further syndicate banks," said Siemens Chief Financial Officer Ralf P. Thomas.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

How CRISPR can help fight against neurodegenerative diseases - Scientists listed ways of applying genetic engineering to treat Parkinson's disease

Stem Cells May Speed Up Screening of Drugs for Rare Cancers

AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus
Removab Approval: Proof-of-Concept for Technology Transfer in Germany

Decoding Blood Platelet Production: The Intricate Role of Lipids - Disruptions in lipid metabolism might affect platelet production

Excessive fluid consumption: habit or hormonal disorder? - Which test provides a reliable diagnosis?

Molecular switch may serve as new target point for cancer and diabetes therapies
HIV/AIDS long-term costs high - and unaffordable to most-affected countries
Part of hagfish slime mystery solved

Effects of chemical mixtures: Neurotoxic effects add up - Study demonstrates for the first time the toxicological relevance of chemical mixtures as they occur in humans

Innovative approach to treat autism spectrum disorders - University of Basel spin-off Translation-X receives Venture Kick funding
